Hendrik-Tobias Arkenau, Ph.D., medical director of Sarah Cannon Research UK, in London discusses three drug trials in colorectal cancer. One supports bevacizumab (Avastin) maintenance therapy in metastatic colorectal cancer. Another produced disappointing results but suggested further investigation of perifosine could be worthwhile. The third is before the FDA, as it considers a proposed indication for regorafenib.